Vectical Receives Expanded Plaque Psoriasis Indication
July 24, 2020Onureg Approved to Treat Acute Myeloid Leukemia
July 24, 2020Breztri Aerosphere Approved as Triple-Combination Maintenance Therapy for COPD
July 24, 2020 – The U.S. FDA has approved Breztri AerosphereTM (budesonide/glycopyrrolate/formoterol fumarate), manufactured by AstraZeneca, to provide maintenance treatment for patients who have chronic obstructive pulmonary disease (COPD).
COPD is a progressive inflammatory disease of the lungs. It causes the airways to constrict and thicken, over time destroying the body’s ability to feed oxygen into its tissues. Breztri Aerosphere is a fixed-dose, triple-combination inhaled therapy that delivers a corticosteroid, a long-acting muscarinic antagonist (LAMA), and a long-acting beta2-agonist (LABA). These types of medications are current standards of care for COPD and work to help reduce inflammation (corticosteroids) and open the airways (LAMAs and LABAs).
In clinical trials, Breztri Aerosphere delivered a statistically significant reduction in the rate of moderate or severe exacerbations of COPD when compared with the use of dual-combination therapies containing either glycopyrrolate and formoterol fumarate, or budesonide and formoterol fumarate. Recommended dosing is two inhalations twice daily.
The product has launched at a wholesale acquisition cost (WAC) of $590.40 per inhaler.
